Actively Recruiting
TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD
Led by Hudson Biotech · Updated on 2026-03-23
80
Participants Needed
1
Research Sites
106 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This fictional study is an example of a ClinicalTrials.gov-style record. It describes a Phase 1/2 trial evaluating the safety and tolerability of TB-500 (a 17-23 fragment of thymosin beta 4) versus placebo in adults with stable atherosclerotic cardiovascular disease (ASCVD). Exploratory endpoints assess vascular function and inflammation biomarkers
CONDITIONS
Official Title
TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 40 to 75 years and able to provide written informed consent
- Documented stable atherosclerotic cardiovascular disease (ASCVD), such as previous myocardial infarction over 6 months ago, prior coronary revascularization, stable angina with evidence of ischemia, or symptomatic peripheral artery disease
- On stable guideline-directed medical therapy, including statins and antiplatelet therapy unless contraindicated, for at least 8 weeks before screening
- Resting systolic blood pressure less than 160 mmHg and diastolic blood pressure less than 100 mmHg, with or without therapy
- Able and willing to comply with study visits and procedures
You will not qualify if you...
- Acute coronary syndrome, stroke, transient ischemic attack, or coronary revascularization within 6 months before screening
- New York Heart Association class III-IV heart failure or left ventricular ejection fraction less than 35%
- Clinically significant arrhythmia requiring recent hospitalization or unstable antiarrhythmic therapy
- Severe renal impairment with eGFR less than 30 mL/min/1.73 m² or end-stage renal disease
- Clinically significant liver impairment such as Child-Pugh class B or C or ALT/AST greater than 3 times the upper limit of normal at screening
- Active cancer requiring systemic treatment within the past 2 years, except treated non-melanoma skin cancer
- Known autoimmune disease needing systemic immunosuppression or use of high-dose systemic corticosteroids
- Pregnant or breastfeeding, or unwilling to use effective contraception if able to become pregnant
- Known allergy to peptide therapies or study formulation components
- Participation in another interventional clinical trial or receipt of an investigational product within 30 days or 5 half-lives before screening
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China, 518036
Actively Recruiting
Research Team
S
Seni Lu, Phd
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here